The association of the <it>PON1 </it>Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis

• Main Authors: Kiessling Matthew, Briggs Patricia J, Hinks Lesley J, Gaunt Tom R, Day Ian NM, Lawlor Debbie A, Timpson Nick, Smith George, Ebrahim Shah
• Format: Article
• Language: English
• Published: BMC 2004-06-01
• Series: BMC Genetics
• Online Access: http://www.biomedcentral.com/1471-2156/5/17

<p>Abstract</p> <p>Background</p> <p>There have been inconsistent results from case-control studies assessing the association of the <it>PON1 </it>Q192R polymorphism with coronary heart disease (CHD). Most studies have included predominantly men and the association in women is unclear. Since lipid levels vary between the sexes the antioxidant effect of PON1 and any genes associated with it may also vary by sex. We have examined the association of the <it>PON1 </it>Q192R polymorphism with CHD in a large cohort of British women and combined the results from our cohort study with those from all other published studies.</p> <p>Results</p> <p>The distribution of genotypes was the same among women with CHD and those without disease. The odds ratio (95% confidence interval) of having CHD comparing those with either the QR or RR genotype to those with QQ genotype (dominant model of association) was 1.03 (0.89, 1.21) and the per allele odds ratio was 0.98 (0.95, 1.01). In a meta-analysis of this and 38 other published studies (10,738 cases and 17,068 controls) the pooled odds ratio for the dominant effect was 1.14 (1.08, 1.20) and for the per allele effect was 1.10 (1.06, 1.13). There was evidence of small study bias in the meta-analyses and the dominant effect among those studies with 500 or more cases was 1.05 (0.96, 1.15). Ethnicity and reporting of whether the genotyping was done blind to the participants clinical status also contributed to heterogeneity between studies, but there was no difference in effect between studies with 50% or more women compared to those with fewer women and no difference between studies of healthy populations compared to those at high risk (with diabetes, renal disease of familial hypercholesterolaemia).</p> <p>Conclusion</p> <p>There is no robust evidence that the <it>PON1 </it>Q192R polymorphism is associated with CHD risk in Caucasian women or men.</p>